Nxera Pharma is the New Name for Sosei Group
31 mars 2024 19h30 HE
|
Nxera Pharma
New name expresses the Company’s vision to lead the next era of medicine - from Japan, for Japan, and by extension, to the world – and its mission to accelerate the development of life-changing...
Sosei Heptares Confirms Re-election of its Board and Executive Management Team and the Approval of Change of Company Name to Nxera Pharma
27 mars 2024 02h45 HE
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 27 March 2024 – Sosei Group Corporation (“the Company”; TSE: 4565) announces that the re-election of its Board of Directors and Executive Officers was approved at the...
Sosei Heptares Doses First Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel Disease
20 mars 2024 20h05 HE
|
Sosei Group Corporation
HTL0033744 has been designed by Sosei Heptares to promote mucosal healing and resolve inflammation in people with IBD Tokyo, Japan and Cambridge, UK, 21 March 2024 – Sosei Group Corporation (“Sosei...
Sosei Heptares Regains Full Ownership from GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease
20 mars 2024 20h01 HE
|
Sosei Group Corporation
GPR35 is a novel target with an established genetic association to IBDUK regulatory approval received to commence first-in-human studiesReturn of rights follows change in immunology research strategy...
Boehringer Ingelheim and Sosei Heptares join forces to develop first-in-class treatments targeting all symptoms of schizophrenia
11 mars 2024 02h38 HE
|
Sosei Group Corporation
Single-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Sosei Heptares with the potential to simultaneously address positive, negative and cognitive...
Sosei Heptares to receive US$2.5 million milestone payment from Formosa Pharmaceuticals
06 mars 2024 02h00 HE
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 6 March 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) announces that Formosa Pharmaceuticals, Inc. (“Formosa”) has received approval...
Sosei Group: Notice of Change of Corporate Name to Nxera Pharma and Change of Location of Head Office
15 févr. 2024 18h35 HE
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 16 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565), today announces that at a meeting held on 15 February 2024, its Board of...
Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023
13 févr. 2024 01h30 HE
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated...
Sosei Heptares Webinar Presentation for FY2023 Financial Results
22 janv. 2024 04h30 HE
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 22 January 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) will announce its earnings results and present operational highlights for the...
Sosei Group Announces Appointment of Experienced Pharmaceutical Executive Toshihiro Maeda as Chief Operating Officer
05 janv. 2024 03h00 HE
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 5 January 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) today announces the appointment of Mr. Toshihiro Maeda as Chief Operating...